date:Feb 26, 2013
from the U.S. market in October 2010 for safety reasons, making these products unapproved new drugs.
Sibutramine is known to substantially increase blood pressure and/or pulse rate in some patients and may present a significant risk to patients with a history of coronary artery disease, congestive heart failure, arrhythmias, or stroke. Sibutramine has been withdrawn from U.S marketplace. The active drug ingredient is not listed on the label for these products. No illnesses or injuries have been